Reforgene presents at BIO-PHARM 2021 on the development and challenges of innovative gene editing medicines
On November 4-5, 2021, the Fifth China Biomedical Innovation Cooperation Conference (BIO-PHARM2021) was grandly held in Guangzhou. The conference focused on current hotspots in the biomedical industry, covering sub-fields such as antibody drugs, gene and cell drugs, and small molecule innovative drugs, building a good academic exchange platform for peers in the biomedical industry. The conference also held the Third Gene and Cell Innovative Therapy Congress in parallel.
Dr. Liang Junbin of Reforgene was invited to attend and delivered a conference speech titled "The Development and Challenges of Innovative Gene Editing Therapies". As an innovative treatment approach, gene therapy brings new treatment options and hope to patients with some incurable diseases. In recent years, innovative gene editing technologies have achieved milestone progress in the treatment of genetic diseases and have gradually expanded to the treatment of some complex diseases and cancer-related indications. In his report, Dr. Liang Junbin started from Reforgene's independently developed, internationally advanced beta-thalassemia gene editing medicine, introducing and discussing the development practices in drug development strategy analysis, solutions to major technical problems, quality methodology development and quality parameter research in the CMC stage during the research and development of this innovative therapy, and shared his understanding of the development and challenges of gene editing medicines at an overall level. The report aroused great interest among the attendees; after the meeting, Dr. Liang Junbin had further in-depth exchanges with the audience, exchanging views on innovation trends in the field.
Conference background
The China Biomedical Innovation Cooperation Conference has been held for five consecutive editions. The Fifth China Biomedical Innovation Cooperation Conference in 2021 was held in Guangzhou, Guangdong Province, organized by Wanyihui and co-organized by the Pharmaceutical Engineering Committee of the Guangdong Pharmaceutical Association and other organizations. Although various industries were impacted to varying degrees by the COVID-19 pandemic in 2020, the number of research activities in the biomedical industry continued to rise, driving the development of next-generation therapies such as cell therapy and gene therapy, and research and venture investment in emerging technologies. Taking this opportunity, the Fifth China Biomedical Innovation Cooperation Conference centered on four special topics: the Antibody Drug Development and Engineering Conference, the Cell and Gene Innovative Therapy Conference, the Innovative Drug and Clinical Trial Conference, and the Small Molecule Innovative Drug Development and Cooperation Conference, inviting more than 100 heavyweight guests from well-known enterprises, universities, research institutes and investment institutions to deliver keynote speeches, and more than 1,000 industry representatives to share the most cutting-edge technology information, interpret the latest industry policies, and comprehensively link multiple platforms across industry, academia, research and capital.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.